When single-stage repair becomes the right conversation

If your knee consultant has mentioned two repair options — one using a scaffold over a marrow-stimulation technique, the other transplanting a plug of your own cartilage — the natural first question is: what makes one more appropriate than the other for my knee?

Both AMIC and OATS share a specific starting point: a focal, full-thickness cartilage defect. This is a discrete area where the articular cartilage has worn through completely, sometimes down to the subchondral bone beneath — not the widespread, diffuse thinning seen in osteoarthritis. Because the damage is contained, restoring that surface is a realistic goal. In clinical grading terms, these are typically ICRS (International Cartilage Repair Society) or Outerbridge grade III to IV lesions: the cartilage has failed in a defined zone, but the surrounding joint remains largely intact.

What both procedures also share is that they are completed in a single operation — one anaesthetic, one hospital admission, no interval wait while cells are cultured in a laboratory. This stands in meaningful contrast to autologous chondrocyte implantation (ACI) and its matrix variant MACI, which require two separate admissions: first to harvest a cartilage biopsy, then — weeks later — to implant the expanded cells. For patients and healthcare systems alike, the single-stage character of AMIC and OATS is a genuine practical advantage.

Beyond that shared ground, the two techniques diverge. The primary decision variables are:

• Defect size — how many square centimetres of cartilage surface are affected
• Depth and subchondral involvement — whether bone beneath the cartilage is intact or compromised
• Location on the knee — femoral condyle, trochlea, or patella each present different geometric challenges
• Patient age and activity level — influencing what the repaired tissue will need to withstand

Neither technique is appropriate where damage is diffuse or end-stage; cartilage repair sits within the joint-preservation pathway, not the replacement pathway. The following sections work through each of these variables in turn.

How OATS works and which defects it suits

OATS — osteochondral autograft transfer — works on a straightforward transplant principle: cylindrical cores of healthy cartilage and the bone beneath it are harvested from a low-stress margin of the same knee, typically the peripheral trochlea or the intercondylar notch, then press-fitted into the prepared defect. Each plug arrives as a complete osteochondral unit — hyaline cartilage sitting on a bed of subchondral bone — restoring both the surface and the structural foundation beneath it in a single step.

Hyaline cartilage is biomechanically closer to native articular tissue than the fibrocartilage produced by marrow-stimulation methods; OATS delivers it immediately, without the regenerative uncertainty that accompanies scaffold-guided chondrogenesis. For defects where the subchondral bone plate is disrupted or collapsed, this combination of cartilage and bone in one graft makes OATS the more direct solution.

Size is the principal constraint. A single plug covers roughly 1–2 cm²; a mosaic arrangement of multiple plugs can extend coverage to approximately 4 cm², though the volume of graft available within the same knee sets a practical ceiling. For most indications, the preferred range sits at or below 2–3 cm² — well-contained, focal, and accessible to the press-fit technique.

Location is also a factor. The cylindrical geometry of an osteochondral plug seats reliably on the curved surface of the femoral condyle. On the trochlea or patella, where curvature is more complex and less uniform, accurate plug seating becomes harder and surface congruity more difficult to achieve.

The meaningful trade-off is donor-site morbidity. Harvesting plugs creates small osteochondral voids within the same knee, and some patients experience persistent discomfort at the harvest site. This is a genuine consideration in patient counselling — not a reason to dismiss OATS, but a factor that weighs more heavily as defect size increases and a larger number of plugs is required to achieve adequate coverage.

How AMIC works and which defects it suits

The question many patients raise is reasonable: if microfracture alone can stimulate some cartilage repair, why overlay anything on top? AMIC exists to address microfracture's main vulnerability.

In microfracture, small perforations through the subchondral bone release marrow stem cells and growth factors — including TGF-β and FGF — into the defect. The resulting blood clot is mechanically fragile; joint movement can dislodge it before stem cells have differentiated into repair tissue. AMIC addresses this by overlaying a resorbable type I/III collagen scaffold — Chondro-Gide® — trimmed to fit and secured over the microfractured surface. The membrane physically retains the marrow clot and guides resident mesenchymal stem cells toward chondrogenic rather than fibrous differentiation.

No donor harvest is required. The scaffold is an exogenous collagen membrane, not a graft taken from within the knee, so there is no donor-site morbidity and no anatomical constraint on the surface area that can be covered. This means AMIC can address contained defects in the range of approximately 2–6 cm² — larger than a single or small cluster of osteochondral plugs can reliably reach. The membrane can also be trimmed to any contour, which is practically useful at irregular sites such as the trochlea and patella where cylindrical plug geometry fits less precisely.

The published evidence base is registry- and cohort-level. The AMIC Registry (Gille et al.; 57 patients, mean age 37.3 years, mean defect size 3.4 cm²) recorded significant VAS pain reductions (p<0.001) and functional score improvements at one and two years. A retrospective series by Schiavoni Panni et al. found the technique effective for full-thickness defects larger than 2 cm² in 21 patients at seven-year follow-up; a randomised trial by Fossum et al. reported outcomes comparable to ACI-C for distal femur and patellar defects.

One limitation should be stated plainly. The scaffold substantially improves on standalone microfracture — whose survivorship falls below 60% at three years — but the tissue that forms is predominantly fibrocartilage rather than true hyaline cartilage. The membrane improves the biologic environment; it does not replicate the native hyaline tissue that an osteochondral plug directly transplants. That tissue-quality gap is one of the central trade-offs when comparing the two techniques.

Defect size, location, and bone depth: the decision framework

Three variables structure the decision between AMIC and OATS: defect size, anatomical location, and the condition of the subchondral bone beneath the lesion. In practice they interact, but working through them in sequence provides a useful clinical framework.

Size comes first. Defects at or below roughly 2–3 cm² are generally well served by OATS: the plug geometry covers the area, donor-site risk remains manageable, and the procedure delivers hyaline cartilage directly. Mid-size contained lesions in the range of approximately 2–6 cm² tend to favour AMIC, where the collagen scaffold can be trimmed to cover the full surface without the constraint of available donor-plug volume.

The overlap zone — around 2–3 cm² — is where the other two variables earn their weight. When a defect in this range sits on the femoral condyle with an intact subchondral plate, OATS remains a strong choice. If the bone beneath the lesion shows cystic change or structural disruption, the osteochondral unit delivered by OATS — which restores bone and cartilage together — becomes more directly relevant. AMIC does not provide structural bone support, making it the less suitable option when subchondral integrity is significantly compromised.

Location shifts the balance further. The cylindrical press-fit geometry of an osteochondral plug seats reliably on the convex femoral condyle. On the trochlea or patella, where surface curvature is less uniform, achieving plug congruity is technically harder; the AMIC membrane, which can be cut to any shape, is more versatile across these anatomically complex sites.

Patient profile adds a final consideration. Younger, more active patients requiring hyaline-quality tissue for smaller lesions lean toward OATS. Where a larger or awkwardly situated defect would demand multiple plugs and a correspondingly higher donor-site burden, AMIC's absence of any harvest penalty carries genuine practical weight.

These criteria rarely align without ambiguity. Most patients sit somewhere in the grey zone between them, and the decision ultimately rests on an experienced consultant assessment — supported by imaging that characterises cartilage depth and subchondral bone structure — rather than on size thresholds alone.

Tissue quality, durability, and what the evidence does and does not show

The tissue type each procedure delivers is the most clearly characterised part of this comparison. OATS transfers true hyaline cartilage — the same biomechanically optimised tissue that lines a healthy knee joint, with the load-distributing and wear-resistant properties that fibrocartilage cannot fully replicate. The scaffold in AMIC improves on bare microfracture by retaining the marrow clot and directing stem cells toward chondrogenesis, but the repair tissue that forms remains predominantly fibrocartilaginous. That gap is real, though its clinical significance at five years may differ from its significance at ten.

On durability, the evidence is asymmetric. OATS carries a 10-year comparative dataset — Gudas et al. (2012) reported superior outcomes versus microfracture at that horizon — which provides a long-term anchor that AMIC cannot yet match. Published AMIC follow-up extends to roughly two to seven years; how fibrocartilage repair tissue performs beyond that range is not well characterised. This is not a reason to dismiss AMIC, but it is a meaningful asymmetry when advising younger patients who may carry the repair for several decades.

What the evidence has not settled is the specific threshold at which OATS donor-site morbidity outweighs its tissue-quality advantage. There is no large head-to-head RCT comparing the two techniques across matched defect sizes in the knee; most comparative insight comes from cohort studies, registries, and systematic reviews.

The practical implication of that gap is concrete: because no published algorithm can yet specify where that balance point falls, it shifts with each patient's anatomy, age, activity level, and tolerance for donor-site risk. Consultant judgment — grounded in imaging that characterises cartilage depth and subchondral bone structure — carries more weight here than any size threshold alone can supply.

Getting an assessment at Lincolnshire Knee

Translating the framework in sections 4 and 5 into a decision for a specific knee requires more than a size measurement. A consultant assessment gathers symptom history, activity demands, and imaging in sequence — the MRI review is particularly important for characterising defect depth, containment, and the integrity of the subchondral bone plate beneath the lesion, all of which bear on whether AMIC or OATS is the more appropriate pathway.

At Lincolnshire Knee, MRI evaluation is supported by onMRI™ AI-driven cartilage analysis, including T2 mapping and segmentation, which helps quantify tissue and bone status objectively. This informs the consultant's judgement; it does not replace it. The decision between techniques — and whether a given defect falls within the treated range for either procedure — is made at a consultant-led appointment, not by algorithm.

No GP referral is needed. Patients can self-refer and be seen without NHS-style waiting times. Consultations and diagnostic imaging are available at the Sleaford NG34 and Grantham NG31 clinics.

Lincolnshire Knee is part of the MSK Doctors group. To arrange an assessment, visit lincolnshireknee.co.uk.

1. [1] Articular Cartilage Repair. https://en.wikipedia.org/?curid=19042351 https://en.wikipedia.org/?curid=19042351
2. [2] Knee Cartilage Replacement Therapy. https://en.wikipedia.org/?curid=4984243 https://en.wikipedia.org/?curid=4984243
3. [3] Autologous Chondrocyte Implantation. https://en.wikipedia.org/?curid=19074150 https://en.wikipedia.org/?curid=19074150